Pharmacological Treatment of Non-Functioning Pituitary Adenomas

• Published in: Archives of medical research Vol. 54; no. 8; p. 102917
• Main Authors: Vargas-Ortega, Guadalupe, Gonzalez-Virla, Baldomero, Romero-Gameros, Carlos Alfonso
• Format: Journal Article
• Language: English
• Published: United States 01.12.2023
• Subjects: Pharmacological treatment; Non-functioning pituitary adenomas; Cabergoline; NFPAs; Pituitary
• ISSN: 0188-4409; 1873-5487
• DOI: 10.1016/j.arcmed.2023.102917

Treatment strategies for NFPA include surgery, radiotherapy, medical treatment, or follow-up. The treatment of NFPAs with compressive symptoms is surgical. However, in case of post-surgical tumor remnants, there may be treatment strategies that include observation and radiotherapy. Recently, medical treatment with cabergoline (CAB) has been recommended to contain and/or reduce the size of the tumor remnant. Based on the findings that many NFPAs show a dopamine receptor (DR) and somatostatin receptor (SR) expression, medical therapy with dopamine agonists (DAs) and somatostatin receptor ligands (SSRLs) has been tested as an alternative to prevent recurrence after surgery. The DAs have been the most extensively studied, showing some potential in terms of tumor shrinkage. SSRLs and other emerging medical options are much less studied. We will review and critically evaluate the current data on the medical therapy of NFPAs to elucidate their role in the management of this tumor type. In the case of actively growing remnants (more than 10% growth per year) and high-risk pituitary adenomas, treatment with CAB at a dose of 1.5-3.0 mg is indicated for tumor containment and/or reduction. In relation to combined chemotherapy with CAB, there is little information in the literature to support its use. In our experience, CAB treatment can be used after radiotherapy as an adjuvant treatment.